CGMP signaling as a target for the prevention and treatment of breast cancer

Seminars in Cancer Biology

Volumn 31, Issue , 2015, Pages 106-110

  Windham, Perrin F ^a   Tinsley, Heather N ^a  

^a UNIVERSITY OF MONTEVALLO   (United States)

Author keywords

Breast cancer; CGMP; GC; NSAID; PKG

Indexed keywords

1 (3 CHLOROANILINO) 4 PHENYLPHTHALAZINE; BETA CATENIN; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; CYCLIN D1; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 8; MULTIDRUG RESISTANCE PROTEIN 5; MYC PROTEIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHODIESTERASE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IX; PHOSPHODIESTERASE V; PHOSPHODIESTERASE VI; SILDENAFIL; SPLEEN EXONUCLEASE; SURVIVIN; TADALAFIL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; GUANOSINE TRIPHOSPHATE; GUANYLATE CYCLASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER INHIBITION; CANCER PREVENTION; CARCINOGENESIS; CELL LEVEL; DOWN REGULATION; DRUG RESPONSE; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; BIOLOGICAL MODEL; BREAST NEOPLASMS; DRUG EFFECTS; FEMALE; METABOLISM;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CYCLIC GMP; FEMALE; GUANOSINE TRIPHOSPHATE; GUANYLATE CYCLASE; HUMANS; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION;

EID: 84923257060     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2014.06.006     Document Type: Review

References (58)

1. Siegel R., DeSantis C., Virgo K., Stein K., Mariotto A., Smith T., et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012, 62(4):220-241.
2. American Cancer Society Breast Cancer Facts and Figures 2009-2010 2009, American Cancer Society, Inc., Atlanta.
3. Berry D.A., Cronin K.A., Plevritis S.K., Fryback D.G., Clarke L., Zelen M., et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005, 353(17):1784-1792.
4. Alberts D.S., Hixson L., Ahnen D., Bogert C., Einspahr J., Paranka N., et al. Do NSAIDs exert their colon cancer chemoprevention activities through the inhibition of mucosal prostaglandin synthetase?. J Cell Biochem Suppl 1995, 22:18-23.
5. Harris R.E., Chlebowski R.T., Jackson R.D., Frid D.J., Ascenseo J.L., Anderson G., et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res 2003, 63(18):6096-6101.
6. Kashfi K., Rigas B. Is COX-2 a 'collateral' target in cancer prevention?. Biochem Soc Trans 2005, 33(Pt 4):724-727.
7. Kwan M.L., Habel L.A., Slattery M.L., Caan B. NSAIDs and breast cancer recurrence in a prospective cohort study. Cancer Causes Control 2007, 18(6):613-620.
8. Piazza G.A., Alberts D.S., Hixson L.J., Paranka N.S., Li H., Finn T., et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 1997, 57(14):2909-2915.
9. Piazza G.A., Keeton A.B., Tinsley H.N., Whitt J.D., Gary B.D., Matthew B., et al. NSAIDs: old drugs reveal new anticancer targets. Pharmaceuticals 2010, 3(5):1652-1667.
10. Raz A. Is inhibition of cyclooxygenase required for the anti-tumorigenic effects of nonsteroidal, anti-inflammatory drugs (NSAIDs)? In vitro versus in vivo results and the relevance for the prevention and treatment of cancer. Biochem Pharmacol 2002, 63(3):343-347.
11. Deguchi A., Thompson W.J., Weinstein I.B. Activation of protein kinase G is sufficient to induce apoptosis and inhibit cell migration in colon cancer cells. Cancer Res 2004, 64(11):3966-3973.
12. Soh J.W., Mao Y., Kim M.G., Pamukcu R., Li H., Piazza G.A., et al. Cyclic GMP mediates apoptosis induced by sulindac derivatives via activation of c-Jun NH2-terminal kinase 1. Clin Cancer Res 2000, 6(10):4136-4141.
13. Thompson W.J., Piazza G.A., Li H., Liu L., Fetter J., Zhu B., et al. Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res 2000, 60(13):3338-3342.
14. Tinsley H.N., Gary B.D., Keeton A.B., Lu W., Li Y., Piazza G.A. Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt/beta-catenin-mediated transcription in human breast tumor cells. Cancer Prev Res (Phila) 2011, 4(8):1275-1284. PMCID: 3151326.
15. Tinsley H.N., Gary B.D., Keeton A.B., Zhang W., Abadi A.H., Reynolds R.C., et al. Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G. Mol Cancer Ther 2009, 8(12):3331-3340. PMCID: 2805153.
16. Rehmann H., Wittinghofer A., Bos J.L. Capturing cyclic nucleotides in action: snapshots from crystallographic studies. Nat Rev Mol Cell Biol 2007, 8(1):63-73.
17. Feil R., Kemp-Harper B. cGMP signalling: from bench to bedside. Conference on cGMP generators, effectors and therapeutic implications. EMBO Rep 2006, 7(2):149-153. PMCID: 1369255.
18. Schulz S., Chinkers M., Garbers D.L. The guanylate cyclase/receptor family of proteins. FASEB J 1989, 3(9):2026-2035.
19. Lincoln T.M., Cornwell T.L. Intracellular cyclic GMP receptor proteins. FASEB J 1993, 7(2):328-338.
20. Omori K., Kotera J. Overview of PDEs and their regulation. Circ Res 2007, 100(3):309-327.
21. Beavo J.A., Brunton L.L. Cyclic nucleotide research - still expanding after half a century. Nat Rev Mol Cell Biol 2002, 3(9):710-718.
22. Beavo J.A. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995, 75(4):725-748.
23. Bender A.T., Beavo J.A. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 2006, 58(3):488-520.
24. Conti M., Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 2007, 76:481-511.
25. Ahn H.S., Crim W., Romano M., Sybertz E., Pitts B. Effects of selective inhibitors on cyclic nucleotide phosphodiesterases of rabbit aorta. Biochem Pharmacol 1989, 38(19):3331-3339.
26. Coquil J.F., Brunelle G., Guedon J. Occurrence of the methylisobutylxanthine-stimulated cyclic GMP binding protein in various rat tissues. Biochem Biophys Res Commun 1985, 127(1):226-231.
27. Francis S.H., Corbin J.D. Purification of cGMP-binding protein phosphodiesterase from rat lung. Methods Enzymol 1988, 159:722-729.
28. Hamet P., Coquil J.F. Cyclic GMP binding and cyclic GMP phosphodiesterase in rat platelets. J Cyclic Nucleotide Res 1978, 4(4):281-290.
29. Kotera J., Fujishige K., Omori K. Immunohistochemical localization of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in rat tissues. J Histochem Cytochem 2000, 48(5):685-693.
30. Lincoln T.M., Hall C.L., Park C.R., Corbin J.D. Guanosine 3':5'-cyclic monophosphate binding proteins in rat tissues. Proc Natl Acad Sci USA 1976, 73(8):2559-2563. PMCID: 430687.
31. Jedlitschky G., Burchell B., Keppler D. The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J Biol Chem 2000, 275(39):30069-30074.
32. Kool M., de Haas M., Scheffer G.L., Scheper R.J., van Eijk M.J., Juijn J.A., et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 1997, 57(16):3537-3547.
33. Ritter C.A., Jedlitschky G., Meyer zu Schwabedissen H., Grube M., Kock K., Kroemer H.K. Cellular export of drugs and signaling molecules by the ATP-binding cassette transporters MRP4 (ABCC4) and MRP5 (ABCC5). Drug Metab Rev 2005, 37(1):253-278.
34. Wielinga P.R., van der Heijden I., Reid G., Beijnen J.H., Wijnholds J., Borst P. Characterization of the MRP4- and MRP5-mediated transport of cyclic nucleotides from intact cells. J Biol Chem 2003, 278(20):17664-17671.
35. Murthy K.S. Activation of phosphodiesterase 5 and inhibition of guanylate cyclase by cGMP-dependent protein kinase in smooth muscle. Biochem J 2001, 360(Pt 1):199-208. PMCID: 1222218.
36. Singer A.L., Sherwin R.P., Dunn A.S., Appleman M.M. Cyclic nucleotide phosphodiesterases in neoplastic and nonneoplastic human mammary tissues. Cancer Res 1976, 36(1):60-66.
37. Karami-Tehrani F., Moeinifard M., Aghaei M., Atri M. Evaluation of PDE5 and PDE9 expression in benign and malignant breast tumors. Arch Med Res 2012, 43(6):470-475.
38. Honorat M., Mesnier A., Vendrell J., Guitton J., Bieche I., Lidereau R., et al. ABCC11 expression is regulated by estrogen in MCF7 cells, correlated with estrogen receptor alpha expression in postmenopausal breast tumors and overexpressed in tamoxifen-resistant breast cancer cells. Endocr Relat Cancer 2008, 15(1):125-138.
39. Mourskaia A.A., Amir E., Dong Z., Tiedemann K., Cory S., Omeroglu A., et al. ABCC5 supports osteoclast formation and promotes breast cancer metastasis to bone. Breast Cancer Res 2012, 14(6):R149.
40. Nooter K., Brutel de la Riviere G., Look M.P., van Wingerden K.E., Henzen-Logmans S.C., Scheper R.J., et al. The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. Br J Cancer 1997, 76(4):486-493. PMCID: 2227995.
41. Saravani R., Karami-Tehrani F., Hashemi M., Aghaei M., Edalat R. Inhibition of phosphodiestrase 9 induces cGMP accumulation and apoptosis in human breast cancer cell lines, MCF-7 and MDA-MB-468. Cell Prolif 2012, 45(3):199-206.
42. Bhowmick R., Girotti A.W. Cytoprotective signaling associated with nitric oxide upregulation in tumor cells subjected to photodynamic therapy-like oxidative stress. Free Radic Biol Med 2013, 57:39-48. PMCID: 3594367.
43. Jadeski L.C., Chakraborty C., Lala P.K. Nitric oxide-mediated promotion of mammary tumour cell migration requires sequential activation of nitric oxide synthase, guanylate cyclase and mitogen-activated protein kinase. Int J Cancer 2003, 106(4):496-504.
44. Kastrati I., Edirisinghe P.D., Wijewickrama G.T., Thatcher G.R. Estrogen-induced apoptosis of breast epithelial cells is blocked by NO/cGMP and mediated by extranuclear estrogen receptors. Endocrinology 2010, 151(12):5602-5616. PMCID: 2999489.
45. Sen S., Kawahara B., Chaudhuri G. Mitochondrial-associated nitric oxide synthase activity inhibits cytochrome c oxidase: implications for breast cancer. Free Radic Biol Med 2013, 57:210-220.
46. Di X., Gennings C., Bear H.D., Graham L.J., Sheth C.M., White K.L., et al. Influence of the phosphodiesterase-5 inhibitor, sildenafil, on sensitivity to chemotherapy in breast tumor cells. Breast Cancer Res Treat 2010, 124(2):349-360.
47. Kumazoe M., Sugihara K., Tsukamoto S., Huang Y., Tsurudome Y., Suzuki T., et al. 67-kDa laminin receptor increases cGMP to induce cancer-selective apoptosis. J Clin Invest 2013, 123(2):787-799. PMCID: 3561824.
48. Deguchi A., Soh J.W., Li H., Pamukcu R., Thompson W.J., Weinstein I.B. Vasodilator-stimulated phosphoprotein (VASP) phosphorylation provides a biomarker for the action of exisulind and related agents that activate protein kinase G. Mol Cancer Ther 2002, 1(10):803-809.
49. Piazza G.A., Thompson W.J., Pamukcu R., Alila H.W., Whitehead C.M., Liu L., et al. Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis. Cancer Res 2001, 61(10):3961-3968.
50. Soh J.W., Kazi J.U., Li H., Thompson W.J., Weinstein I.B. Celecoxib-induced growth inhibition in SW480 colon cancer cells is associated with activation of protein kinase G. Mol Carcinog 2008, 47(7):519-525.
51. Tinsley H.N., Gary B.D., Thaiparambil J., Li N., Lu W., Li Y., et al. Colon tumor cell growth-inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition. Cancer Prev Res (Phila) 2010, 3(10):1303-1313. PMCID: 2955813.
52. Whitehead C.M., Earle K.A., Fetter J., Xu S., Hartman T., Chan D.C., et al. Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival. Mol Cancer Ther 2003, 2(5):479-488.
53. Thompson H.J., Jiang C., Lu J., Mehta R.G., Piazza G.A., Paranka N.S., et al. Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res 1997, 57(2):267-271.
54. Fallahian F., Karami-Tehrani F., Salami S. Induction of apoptosis by type Ibeta protein kinase G in the human breast cancer cell lines MCF-7 and MDA-MB-468. Cell Biochem Funct 2012, 30(3):183-190.
55. Fallahian F., Karami-Tehrani F., Salami S., Aghaei M. Cyclic GMP induced apoptosis via protein kinase G in oestrogen receptor-positive and -negative breast cancer cell lines. FEBS J 2011, 278(18):3360-3369.
56. Isshiki K., Matsuda S., Tsuji A., Yuasa K. cGMP-dependent protein kinase I promotes cell apoptosis through hyperactivation of death-associated protein kinase 2. Biochem Biophys Res Commun 2012, 422(2):280-284.
57. Wong J.C., Bathina M., Fiscus R.R. Cyclic GMP/protein kinase G type-Ialpha (PKG-Ialpha) signaling pathway promotes CREB phosphorylation and maintains higher c-IAP1, livin, survivin, and Mcl-1 expression and the inhibition of PKG-Ialpha kinase activity synergizes with cisplatin in non-small cell lung cancer cells. J Cell Biochem 2012, 113(11):3587-3598.
58. King T.D., Suto M.J., Li Y. The Wnt/beta-catenin signaling pathway: a potential therapeutic target in the treatment of triple negative breast cancer. J Cell Biochem 2012, 113(1):13-18.